为筛选出在前列腺癌和前列腺增生组织中差异表达的miRNA，并验证其与前列腺癌的关联。选取2021年10月至2022年6月于新疆医科大学第一附属医院泌尿外科病理确诊的患者，收集其一般临床信息、血样和前列腺组织样品。使用miRNA芯片技术，获得前列腺癌和增生组织中差异表达的miRNA，并通过芯片结果和相关文献的回顾筛选出待研究的miRNA。测定患者血样和前列腺组织样品中miRNA的表达情况。将miRNA-222-mimics转染至PC3细胞，进行CCK8、划痕、Transwell和流式细胞术等细胞生物学实验，检测过表达miRNA-222对前列腺癌细胞生长和增殖、侵袭能力、凋亡能力和转移能力的影响。 miRNA芯片的结果显示，在前列腺癌和增生组织中存在许多差异表达的miRNA，最终通过相关文献回顾选定了miRNA-144、miRNA-222、miRNA-1248和miRNA-3651作为研究对象。结果显示，在前列腺癌组织中，miRNA-222的表达水平低于前列腺增生组织（P < 0.05）。前列腺癌患者血样中的miRNA-222、miRNA-1248和miRNA-3651的表达水平低于前列腺增生患者（P < 0.05）。分析结果表明，f/t比值和miRNA-222、miRNA-1248的相对表达是前列腺癌的独立影响因素（P < 0.05）。miRNA-222的过表达降低了PC3细胞的增殖、侵袭和转移能力，并增加了癌细胞的凋亡水平。 尽管本研究中前列腺癌的总发病率没有显著变化，但不同特征的前列腺癌发病率发生了显著变化。此外，基于四个因素构建的前列腺癌特异性生存率Nomogram预测模型具有很高的参考价值，有助于医生正确评估患者的个体生存率，并为患者的诊断和预后评估提供参考依据。© 2023. BioMed Central（Springer Nature的一部分）。

To screen for miRNAs differentially expressed in prostate cancer and prostate hyperplasia tissues and to validate their association with prostate cancer.Patients diagnosed by pathology in the Department of Urology of the First Affiliated Hospital of Xinjiang Medical University from October 2021 to June 2022 were selected, and their general clinical information, blood samples, and prostate tissue samples were collected. miRNA microarray technology was performed to obtain differentially expressed miRNAs in prostate cancer and hyperplasia tissues, and miRNAs to be studied were screened by microarray results and review of relevant literature. The detection of miRNA expression in the patients' blood and prostate tissue samples was measured. The miRNA-222-mimics were transfected into PC3 cells, and cell biology experiments such as CCK8, scratch, Transwell, and flow cytometry were performed to detect the effects of overexpressed miRNA-222 on the growth and proliferation, invasive ability, apoptotic ability, and metastatic ability of prostate cancer cells.The results of the miRNA microarray showed that there were many differentially expressed miRNAs in prostate cancer and hyperplasia tissues, and four miRNAs, miRNA-144, miRNA-222, miRNA-1248, and miRNA-3651 were finally selected as the subjects by reviewing relevant literature. The results showed that the expression of miRNA-222 in prostate cancer tissues was lower than that in prostate hyperplasia tissues (P < 0.05). The expression of miRNA-222, miRNA-1248, and miRNA-3651 in blood samples of prostate cancer patients was lower than that in prostate hyperplasia patients (P < 0.05). The analysis results indicated that the f/t ratio and the relative expression of miRNA-222 and miRNA-1248 were independent influences of prostate cancer (P < 0.05), in which overexpression of miRNA-222 decreased the proliferative, invasive, and metastatic abilities of PC3 cells and enhanced the level of apoptosis of cancer cells.Although there was no significant change in the overall incidence of prostate cancer in this study, significant changes occurred in the incidence of prostate cancer with different characteristics. In addition, the nomogram prediction model of prostate cancer-specific survival rate constructed based on four factors has a high reference value, which helps physicians to correctly assess the patient-specific survival rate and provides a reference basis for patient diagnosis and prognosis evaluation.© 2023. BioMed Central Ltd., part of Springer Nature.